Top

Published in:

Open Access 01-07-2012 | Original paper

Prediagnostic concentrations of plasma genistein and prostate cancer risk in 1,605 men with prostate cancer and 1,697 matched control participants in EPIC

Authors: Ruth C. Travis, Naomi E. Allen, Paul N. Appleby, Alison Price, Rudolf Kaaks, Jenny Chang-Claude, Heiner Boeing, Krasimira Aleksandrova, Anne Tjønneland, Nina Føns Johnsen, Kim Overvad, J. Ramón Quirós, Carlos A. González, Esther Molina-Montes, Maria José Sánchez, Nerea Larrañaga, José María Huerta Castaño, Eva Ardanaz, Kay-Tee Khaw, Nick Wareham, Antonia Trichopoulou, Tina Karapetyan, Snorri Bjorn Rafnsson, Domenico Palli, Vittorio Krogh, Rosario Tumino, Paolo Vineis, H. Bas Bueno-de-Mesquita, Pär Stattin, Mattias Johansson, Veronika Fedirko, Teresa Norat, Afshan Siddiq, Elio Riboli, Timothy J. Key

Published in: Cancer Causes & Control | Issue 7/2012

Abstract

Purpose

Data from prospective epidemiological studies in Asian populations and from experimental studies in animals and cell lines suggest a possible protective association between dietary isoflavones and the development of prostate cancer. We examined the association between circulating concentrations of genistein and prostate cancer risk in a case–control study nested in the European Prospective Investigation into Cancer and Nutrition.

Methods

Concentrations of the isoflavone genistein were measured in prediagnostic plasma samples for 1,605 prostate cancer cases and 1,697 matched control participants. Relative risks (RRs) for prostate cancer in relation to plasma concentrations of genistein were estimated by conditional logistic regression.

Results

Plasma genistein concentrations were not associated with prostate cancer risk; the multivariate relative risk for men in the highest fifth of genistein compared with men in the lowest fifth was 1.00 (95 % confidence interval: 0.79, 1.27; p linear trend = 0.82). There was no evidence of heterogeneity in this association by age at blood collection, country of recruitment, or cancer stage or histological grade.

Conclusion

Plasma genistein concentration was not associated with prostate cancer risk in this large cohort of European men.

Hwang YW, Kim SY, Jee SH, Kim YN, Nam CM (2009) Soy food consumption and risk of prostate cancer: a meta-analysis of observational studies. Nutr Cancer 61:598–606PubMedCrossRef

Yan L, Spitznagel EL (2009) Soy consumption and prostate cancer risk in men: a revisit of a meta-analysis. Am J Clin Nutr 89:1155–1163PubMedCrossRef

Perabo FG, Von Low EC, Ellinger J, von Rucker A, Muller SC, Bastian PJ (2008) Soy isoflavone genistein in prevention and treatment of prostate cancer. Prostate Cancer Prostatic Dis 11:6–12PubMedCrossRef

Liggins J, Mulligan A, Runswick S, Bingham SA (2002) Daidzein and genistein content of cereals. Eur J Clin Nutr 56:961–966PubMedCrossRef

Rowland I, Faughnan M, Hoey L, Wahala K, Williamson G, Cassidy A (2003) Bioavailability of phyto-oestrogens. Br J Nutr 89(Suppl 1):S45–S58PubMed

Ozasa K, Nakao M, Watanabe Y, Hayashi K, Miki T, Mikami K et al (2004) Serum phytoestrogens and prostate cancer risk in a nested case-control study among Japanese men. Cancer Sci 95:65–71PubMedCrossRef

Kurahashi N, Iwasaki M, Inoue M, Sasazuki S, Tsugane S (2008) Plasma isoflavones and subsequent risk of prostate cancer in a nested case-control study: the Japan Public Health Center. J Clin Oncol 26:5923–5929PubMedCrossRef

Travis RC, Spencer EA, Allen NE, Appleby PN, Roddam AW, Overvad K et al (2009) Plasma phyto-oestrogens and prostate cancer in the European Prospective Investigation into Cancer and Nutrition. Br J Cancer 100:1817–1823PubMedCrossRef

Riboli E, Hunt KJ, Slimani N, Ferrari P, Norat T, Fahey M et al (2002) European Prospective Investigation into Cancer and Nutrition (EPIC): study populations and data collection. Public Health Nutr 5:1113–1124PubMedCrossRef

10.

Grace PB, Mistry NS, Carter MH, Leathem AJ, Teale P (2007) High throughput quantification of phytoestrogens in human urine and serum using liquid chromatography/tandem mass spectrometry (LC-MS/MS). J Chromatogr B Analyt Technol Biomed Life Sci 853:138–146PubMedCrossRef

11.

Rosner B (1982) On the estimation and testing of interclass correlations: the general case of multiple replicates for each variable. Am J Epidemiol 116:722–730PubMed

12.

StataCorp (2007) Stata statistical software: release 10. StataCorp LP, College Station, TX

13.

Peeters PH, Slimani N, van der Schouw YT, Grace PB, Navarro C, Tjonneland A et al (2007) Variations in plasma phytoestrogen concentrations in European adults. J Nutr 137:1294–1300PubMed

14.

Ward H, Chapelais G, Kuhnle GG, Luben R, Khaw KT, Bingham S (2008) Lack of prospective associations between plasma and urinary phytoestrogens and risk of prostate or colorectal cancer in the European Prospective into Cancer-Norfolk study. Cancer Epidemiol Biomarkers Prev 17:2891–2894PubMedCrossRef

15.

McCarty MF (2006) Isoflavones made simple-genistein’s agonist activity for the beta-type estrogen receptor mediates their health benefits. Med Hypotheses 66:1093–1114PubMedCrossRef

16.

D’Ambrosio G, Samani F, Cancian M, De Mola C (2004) Practice of opportunistic prostate-specific antigen screening in Italy: data from the Health Search database. Eur J Cancer Prev 13:383–386PubMedCrossRef

17.

Melia J, Moss S, Johns L (2004) Rates of prostate-specific antigen testing in general practice in England and Wales in asymptomatic and symptomatic patients: a cross-sectional study. BJU Int 94:51–56PubMedCrossRef

18.

Otto SJ, van der Cruijsen IW, Liem MK, Korfage IJ, Lous JJ, Schroder FH et al (2003) Effective PSA contamination in the Rotterdam section of the European randomized study of screening for prostate cancer. Int J Cancer 105:394–399PubMedCrossRef

19.

Paez A, Lujan M, Llanes L, Romero I, de la Cal MA, Miravalles E et al (2002) PSA-use in a Spanish industrial area. Eur Urol 41:162–166PubMedCrossRef

20.

Etzioni R, Penson DF, Legler JM, di Tommaso D, Boer R, Gann PH et al (2002) Overdiagnosis due to prostate-specific antigen screening: lessons from U.S. prostate cancer incidence trends. J Natl Cancer Institute 94:981–990CrossRef

21.

Grace PB, Taylor JI, Low YL, Luben RN, Mulligan AA, Botting NP et al (2004) Phytoestrogen concentrations in serum and spot urine as biomarkers for dietary phytoestrogen intake and their relation to breast cancer risk in European Prospective Investigation of Cancer and Nutrition-Norfolk. Cancer Epidemiol Biomarkers Prev 13:698–708PubMed

22.

Zeleniuch-Jacquotte A, Adlercreutz H, Akhmedkhanov A, Toniolo P (1998) Reliability of serum measurements of lignans and isoflavonoid phytoestrogens over a two-year period. Cancer Epidemiol Biomarkers Prev 7:885–889PubMed

23.

Fraser GE, Franke AA, Jaceldo-Siegl K, Bennett H (2010) Reliability of serum and urinary isoflavone estimates. Biomarkers 15:135–139PubMedCrossRef

Title: Prediagnostic concentrations of plasma genistein and prostate cancer risk in 1,605 men with prostate cancer and 1,697 matched control participants in EPIC
Authors: Ruth C. Travis
Naomi E. Allen
Paul N. Appleby
Alison Price
Rudolf Kaaks
Jenny Chang-Claude
Heiner Boeing
Krasimira Aleksandrova
Anne Tjønneland
Nina Føns Johnsen
Kim Overvad
J. Ramón Quirós
Carlos A. González
Esther Molina-Montes
Maria José Sánchez
Nerea Larrañaga
José María Huerta Castaño
Eva Ardanaz
Kay-Tee Khaw
Nick Wareham
Antonia Trichopoulou
Tina Karapetyan
Snorri Bjorn Rafnsson
Domenico Palli
Vittorio Krogh
Rosario Tumino
Paolo Vineis
H. Bas Bueno-de-Mesquita
Pär Stattin
Mattias Johansson
Veronika Fedirko
Teresa Norat
Afshan Siddiq
Elio Riboli
Timothy J. Key
Publication date: 01-07-2012
Publisher: Springer Netherlands
Published in: Cancer Causes & Control / Issue 7/2012
Print ISSN: 0957-5243
Electronic ISSN: 1573-7225
DOI: https://doi.org/10.1007/s10552-012-9985-y

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Purpose

Methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 7/2012

The association of diabetes with breast cancer incidence and mortality in the Long Island Breast Cancer Study Project

Sun exposure and risk of lymphoid neoplasms in Singapore

Serum 25-hydroxyvitamin D and risk of breast cancer: results of a large population-based case–control study in Mexican women

Genetic variants in IGF-I, IGF-II, IGFBP-3, and adiponectin genes and colon cancer risk in African Americans and Whites

Prostate cancer mortality and birth or adult residence in the southern United States

Evolution of Cancer Control P.L.A.N.E.T.: moving research into practice

Keynote webinar | Spotlight on antibody–drug conjugates in cancer